Results 91 to 100 of about 21,053 (285)

Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease

Journal of interventional cardiology, 2022
Background Current guidelines recommend an oral anticoagulant (OAC) monotherapy in patients with nonvalvular atrial fibrillation (NVAF) and stable coronary artery disease (CAD) 1 year postpercutaneous coronary intervention (PCI).
D. Fukamachi, Yasuo Okumura, N. Matsumoto, E. Tachibana, K. Oiwa, M. Ichikawa, H. Haruta, K. Nomoto, K. Arima, A. Hirayama   +9 more
semanticscholar   +1 more source

The Risk of Colonoscopy‐related Bleeding in Patients With or Without Continued Treatment With an Antithrombotic Agent

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Objectives We prospectively investigated the risk of colonoscopy‐related bleeding in relation to antithrombotic treatment. Methods This prospective, observational, single‐center cohort study (NCT02594813) enrolled consecutive patients who underwent colonoscopy, including the removal of colorectal polyps, regardless of the continuation of ...
Emi Nonaka, Ichitaro Horiuchi, Akira Horiuchi, Satoshi Ukai, Noriko Takahata, Kimihiko Oishi   +5 more
wiley   +1 more source

Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials. [PDF]

PLoS ONE, 2014
Edoxaban, a factor Xa inhibitor, is a new oral anticoagulant that has been developed as an alternative to vitamin K antagonists. However, its safety remains unexplored.Medline, Embase and Web of Science were searched to March 8, 2014 for prospective ...
Shuang Li, Baoxin Liu, Dachun Xu, Yawei Xu   +3 more
doaj   +1 more source

Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. [PDF]

, 2018
© 2018 Vimalesvaran et al. This work is published and licensed by Dove Medical Press Limited.Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and it leads to significant morbidity and mortality, predominantly from ischemic stroke.
Dockrill, Seth J, Gorog, Diana, Vimalesvaran, Kavitha   +2 more
core   +3 more sources

Comparative effectiveness and safety of edoxaban, rivaroxaban, and apixaban in patients with venous thromboembolism: A cohort study

Journal of Thrombosis and Haemostasis, 2022
Although several studies have compared the effectiveness and safety of rivaroxaban and apixaban in patients with venous thromboembolism (VTE), direct comparison of these drugs with edoxaban is lacking.
Toshiki Fukasawa, Tomotsugu Seki, Masayuki Nakashima, K. Kawakami   +3 more
semanticscholar   +1 more source

Distribution of anti‐factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban

Journal of Arrhythmia
Background The distribution of anti‐factor Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) taking edoxaban 15 mg has not been fully elucidated. Methods and Results The trough and peak AXA were measured in 19 NVAF patients taking
Shotaro Hiramatsu, Hiroyuki Osanai, Yuichiro Sakai, Yoshiki Sogo, Yuki Tanaka, Hikari Matsumoto, Shun Miyamoto, Kensuke Tagahara, Kenji Arai, Takashi Watanabe, Yusuke Sakamoto, Teruhiro Sakaguchi, Shioh Oguchi, Takahiro Kanbara, Yoshihito Nakashima, Hiroshi Asano, Masayoshi Ajioka   +16 more
doaj   +1 more source

Direct oral anticoagulants versus warfarin: is new always better than the old? [PDF]

, 2018
About 1.4 British million people are at risk of strokes due to non-valvular atrial fibrillation (AF) necessitating long-term anticoagulation. The vitamin K antagonist, warfarin, has a long half-life and narrow therapeutic range necessitating regular ...
Burn, John, Pirmohamed, Munir
core   +1 more source

Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study

European Heart Journal - Cardiovascular Pharmacotherapy
Background The ONCO DVT study revealed the superiority of 12-month relative to 3-month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (DVT) regarding the thrombotic risk.
R. Chatani, Y. Yamashita, Takeshi Morimoto, N. Muraoka, M. Umetsu, Y. Nishimoto, T. Takada, Y. Ogihara, T. Nishikawa, Nobutaka Ikeda, K. Otsui, D. Sueta, Y. Tsubata, M. Shoji, A. Shikama, Y. Hosoi, Y. Tanabe, K. Tsukahara, N. Nakanishi, Kitae Kim, S. Ikeda, K. Mushiake, K. Kadota, Koh Ono, T. Kimura   +24 more
semanticscholar   +1 more source

Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation in Cardiac Amyloidosis

Journal of Arrhythmia, Volume 42, Issue 1, February 2026.
Left atrial appendage occlusion‐related outcomes in patients with amyloid cardiomyopathy. ABSTRACT Background Cardiac amyloidosis (CA) is frequently complicated by atrial fibrillation (AF), yet outcomes after left atrial appendage occlusion (LAAO) in this population remain poorly defined.
Abdul Hakim Almakadma, Ramzi Ibrahim, Hoang Nhat Pham, Eiad Habib, Ahmed K. Mahmoud, Kamal Awad, Mayurkumar D. Bhakta, Eric H. Yang, Hicham Z. El Masry, Chadi Ayoub, Reza Arsanjani   +10 more
wiley   +1 more source

Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. [PDF]

, 2018
It is common knowledge that cancer patients are more prone to develop venous thromboembolic complications (VTE). It is therefore not surprising that patients with hepatocellular carcinoma (HCC) present with a significant risk of VTE, with the portal vein
Burra, P, Campello, E, Russo, Fp., Simioni, P, Spiezia, L, Zanetto, A   +5 more
core   +1 more source